Impact of very low anti-Müllerian hormone on pregnancy success

Curr Opin Obstet Gynecol. 2017 Jun;29(3):131-135. doi: 10.1097/GCO.0000000000000354.

Abstract

Purpose of review: Biomarkers are useful tool to help clinicians to estimate the chances of pregnancy of an infertile couple prior to assisted reproductive treatment. One proposed candidate is anti-Müllerian hormone (AMH), but its role as a predictor of reproductive success, especially in patients with low or very low levels, is under discussion. This review highlights recent findings from literature regarding to reproductive outcome in women with very low levels of AMH.

Recent findings: Although there is a general agreement about the lower pregnancy rates of patients with very low levels of AMH compared with patients with normal AMH levels, the role of AMH as a predictor of success is still under discussion. In this sense, some authors establish a cutoff level below which the reproduction treatment is not successful; by contrast, other published data show a significant percentage of success is still observed in this group of patients, especially in young women.

Summary: In the following review, we discuss the usefulness of AMH as a predictor of reproductive outcome in patients with very low AMH levels and provide an update of the clinical results after assisted reproductive treatment in this group of patients. We also analyzed the different assays used to measure the AMH, focused on the differences between the manual and the new automated systems.

Publication types

  • Review

MeSH terms

  • Anti-Mullerian Hormone / blood*
  • Biomarkers / blood
  • Female
  • Humans
  • Immunoassay / methods
  • Live Birth
  • Maternal Age
  • Ovarian Reserve
  • Pregnancy
  • Pregnancy Rate*
  • Reproductive Techniques, Assisted

Substances

  • Biomarkers
  • Anti-Mullerian Hormone